VANCOUVER, BC–(Marketwired – February 02, 2018) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Paris symposium: Adaptations in Polar Environments and Biomimicry.
The conference showcases animal adaptations to extreme polar environments, and how these adaptations have inspired commercial technology. Dr. Deliencourt-Godefroy will present on February 3rd at 11:00 AM CET, on the glycoproteins that were discovered in Arctic fishes and her advancement of the technology in human cell preservation. Her talk can be streamed live at:
NB: the conference is held in French.
About Milieux Polaires et Biomimétisme and Poles Actions
The yearly symposium is organized by Poles Actions and is dedicated to polar biomimicry.
The association of Poles Actions is intended to promote the knowledge and the protection of Arctic and Antarctic ecosystems through awareness, education and support for research in polar and subpolar regions. It acts as a nonpartisan, objective and scientifically credible channel of communication, based on the activities and experience of its members and external stakeholders. It organizes educational interventions, exhibitions, conferences and scientific expeditions to help publicize and protect these fragile ecosystems. For more information, visit: http://www.ourspolaire.org/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Sirona Biochem Corp.